Neurocrine Biosciences, Inc. today announced the launch of a new sprinkle formulation of INGREZZA® (valbenazine) capsules, the #1 prescribed vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease. INGREZZA® SPRINKLE (valbenazine) capsules is now available through the same network of specialty and local affiliated pharmacies that distribute INGREZZA.
New Sprinkle Formulation of INGREZZA® for Chorea
July 18, 2024
For more information about HDYO visit our website
www.hdyo.org